Neuphoria Therapeutics (NEUP) Short-term Investments (2021 - 2025)
Neuphoria Therapeutics (NEUP) reported Short-term Investments of $79647.0 for Q4 2025, up 1.38% on a QoQ basis from $78564.0 in Q3 2025.
Neuphoria Therapeutics (NEUP) has 2 years of Short-term Investments data on file, last reported at $79647.0 in Q4 2025.
- Quarterly Short-term Investments changed N/A year-over-year to $79647.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $79647.0 (changed N/A YoY) and the FY2025 annual result came in at $77945.0, changed N/A from the prior year.
- Short-term Investments grew to $79647.0 in Q4 2025 per NEUP's latest filing, from $78564.0 in the prior quarter.
- Across five years, Short-term Investments topped out at $335466.8 in Q2 2021 and bottomed at $77945.0 in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Neuphoria Therapeutics | 28.35 Mn | 8.95 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 79,647.00 |
| Sep 30, 2025 | 78,564.00 |
| Jun 30, 2025 | 77,945.00 |
| Dec 31, 2021 | 86,691.59 |
| Jun 30, 2021 | 335,466.82 |